Depo-Provera

Known as: depo-provera contraceptive, provera depo, DepoProvera 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1963-2018
0102019632018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Depo-Provera is a highly effective contraceptive, given intramuscularly (150 mg/mL) once every 3 months. It has been in use in… (More)
Is this relevant?
2004
2004
The aim of this study was to determine the effectiveness of medroxyprogesterone acetate (Depo Provera) in the treatment of… (More)
Is this relevant?
2000
2000
  • Eve Espeya, Jonathan Steinhartb, Tony Ogburna, Clifford Quallsc
  • 2000
Depo-medroxyprogesterone acetate (DMPA) is an increasingly popular contraceptive choice among Navajo women. Weight gain is cited… (More)
  • table 2
  • table 1
  • table 3
Is this relevant?
1999
1999
Two studies in rhesus monkeys have shown that progesterone implants, Depo-Provera and Norplant, were associated with vaginal… (More)
Is this relevant?
1998
1998
Women enrolled in a multicenter prospective study were evaluated to identify any possible relationship between depressive… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
OBJECTIVE To examine bone density among adolescents receiving different forms of hormonal contraception along with that of… (More)
Is this relevant?
1990
1990
Medroxyprogesterone acetate (MPA) is capable of reducing male testosterone blood levels with a corresponding reduction in sexual… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1989
1989
OBJECTIVE To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the… (More)
  • table III
  • table IV
  • table V
  • table VI
Is this relevant?
1980
1980
This article discusses the research which has led to the controversy of Depo-Provera, and delineates the risks discovered as a… (More)
Is this relevant?
1980
1980
A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma… (More)
Is this relevant?